drugset

drugset / Trial / NCT00721201

Glucocorticoid Receptor Antagonism in Subclinical Cushings

NCT00721201 ↗

Phase 1/2 Completed 6 enrolled Sheffield Teaching Hospitals NHS Foundation Trust HRA Pharma · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effects of reducing the activity of endogenous glucocorticoid in patients with low-grade cortisol excess

Timeline

Start: 2008-11
Primary completion: 2010-03
Completion: 2010-03

Publications

Debono M, Chadarevian R, Eastell R, Ross RJ, Newell-Price J. Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study. PLoS One. 2013;8(4):e60984. doi: 10.1371/journal.pone.0060984. Epub 2013 Apr 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mifepristone	Small molecule	200 mg	—

Indications